Casdin Capital Portfolio

Casdin Capital 13F filer (CIK 0001534261).

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2021 · 54 positions · Total reported value $3.94B · Top-10 concentration 57.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 26.1% · 6 new · 3 cut · 3 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2021 13F filing, Casdin Capital disclosed 54 equity positions with a combined reported value of $3.94B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 57.2% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2021 were NVTAQ ($411.63M), BLFS ($331.16M), FATE ($295.09M). By sector, the heaviest allocations are Health Care 54.8%, Industrials 7.6%. Versus the prior quarter, allocation shifted toward Health Care (+1.7pp) and away from Other (-0.6pp), Industrials (-1.1pp).

Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 73% of names.

The largest new positions opened in Q2 2021 were VERV ($183.05M), IPSC ($94.08M), OMIC ($74.00M).

Of the 3 positions fully exited versus the prior quarter, the largest were BNR ($22.80M), ADVM ($21.81M), TSHA ($16.66M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2021)

  • VERV VERVE THERAPEUTICS INC · $183.05M
  • IPSC CENTURY THERAPEUTICS INC · $94.08M
  • OMIC OPTIMA MED INNOVATIONS F · $74.00M
  • AMRSQ AMYRIS INC · $49.11M
  • ME 23ANDME HOLDING CO · $32.05M
  • NEO NEOGENOMICS INC · $22.08M
  • GLUE MONTE ROSA THERAPEUTICS · $21.81M
  • RXRX RECURSION PHARMACEUTICALS IN · $20.01M

Fully Exited (vs previous quarter)

  • BNR BURNING ROCK BIOTECH LTD · prev qtr: $22.80M
  • ADVM ADVERUM BIOTECHNOLOGIES INC · prev qtr: $21.81M
  • TSHA TAYSHA GENE THERAPIES IN · prev qtr: $16.66M · history
  • DYN DYNE THERAPEUTICS INC · prev qtr: $9.47M
  • CDAKQ CODIAK BIOSCIENCES INC · prev qtr: $1.16M

Insider Transactions (Form 4)

Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-110894 (status: Approved), registered 2017-07-31
  • Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds

Portfolio Structure

  • 43 positions · $2.00B reported value (Q2 2026)
  • Top 10 holdings = 77.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
  • Average position size: $46.46M

Sector Tilt

  • Health Care 94.2%
  • Industrials 5.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
  • 25 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 54.8%
Other 37.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.20M $411.63M 10.45%
10.45%
Hold
2 7.44M $331.16M 8.41%
8.41%
Hold
3 3.40M $295.09M 7.49%
7.49%
Hold
4 2.36M $293.39M 7.45%
7.45%
Hold
5 3.04M $183.05M 4.65%
4.65%
New
6 5.00M $174.85M 4.44%
4.44%
Hold
7 1.00M $169.52M 4.30%
4.30%
Add
8 1.55M $136.34M 3.46%
3.46%
Hold
9 1.00M $133.25M 3.38%
3.38%
Hold
10 1.61M $126.29M 3.21%
3.21%
Hold
11 3.38M $123.49M 3.13%
3.13%
Hold
12 2.17M $119.31M 3.03%
3.03%
Hold
13 1.19M $109.21M 2.77%
2.77%
Hold
14 818.82K $105.39M 2.67%
2.67%
Hold
15 4.33M $98.12M 2.49%
2.49%
Hold
16 3.21M $94.08M 2.39%
2.39%
New
17 2.69M $74.00M 1.88%
1.88%
New
18 2.31M $73.16M 1.86%
1.86%
Add
19 1.75M $72.54M 1.84%
1.84%
Hold
20 885.00K $68.80M 1.75%
1.75%
Add
21 1.44M $58.84M 1.49%
1.49%
Add
22 150.00K $51.48M 1.31%
1.31%
Hold
23 3.00M $49.11M 1.25%
1.25%
New
24 1.31M $45.88M 1.17%
1.17%
Add
25 1.34M $45.33M 1.15%
1.15%
Reduce
26 1.61M $43.34M 1.10%
1.10%
Hold
27 266.43K $43.13M 1.09%
1.09%
Hold
28 1.65M $34.37M 0.87%
0.87%
Hold
29 190.00K $33.63M 0.85%
0.85%
Hold
30 3.35M $32.72M 0.83%
0.83%
Hold
31 2.74M $32.05M 0.81%
0.81%
New
32 1.23M $31.95M 0.81%
0.81%
Reduce
33 1.12M $26.86M 0.68%
0.68%
Add
34 488.89K $22.08M 0.56%
0.56%
New
35 960.88K $21.81M 0.55%
0.55%
New
36 1.20M $20.60M 0.52%
0.52%
Add
37 548.16K $20.01M 0.51%
0.51%
New
38 406.50K $15.75M 0.40%
0.40%
Hold
39 3.22M $14.12M 0.36%
0.36%
Hold
40 583.44K $13.97M 0.35%
0.35%
Hold
41 1.15M $12.10M 0.31%
0.31%
Reduce
42 601.51K $10.64M 0.27%
0.27%
Hold
43 1.17M $10.07M 0.26%
0.26%
Add
44 726.51K $9.68M 0.25%
0.25%
Hold
45 200.00K $8.96M 0.23%
0.23%
Hold
46 300.00K $7.12M 0.18%
0.18%
New
47 550.00K $6.58M 0.17%
0.17%
Hold
48 75.00K $5.85M 0.15%
0.15%
Hold
49 500.00K $5.05M 0.13%
0.13%
New
50 150.00K $4.92M 0.12%
0.12%
Hold

FAQ

What did Casdin Capital buy in 2021-Q2?

In its 2021-Q2 13F filing, Casdin Capital reported 54 equity positions worth $3.94B in aggregate; its largest disclosed positions were NVTAQ ($411.63M), BLFS ($331.16M), FATE ($295.09M).

How large is Casdin Capital's portfolio?

Casdin Capital reported $3.94B of long equity holdings across 54 positions as of 2021-Q2. Top-10 holdings account for 57.2% of reported value.

What is Casdin Capital's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/casdin/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →